R&D
JW, leading global new drug development
Research Pipeline
CreaVax-HCC
-
Summary of Phase II clinical trial- CreaVax-HCC was well tolerated to firstly diagnosed early HCC patients.
- CreaVax-HCC showed significant inhibition of tumor recurrence with curative hepatic resection suggesting increase of recurrence free survival in two years
-
Summary of Phase III clinical trial- Study design : A Multi-centered, randomized, double-blind, placebo-controlled Phase III study on the efficacy and safety of CreaVax-HCC in patients with hepatocellular carcinoma for comparing after curative hepatic resection
- Target patients: Early HCC patients after curative hepatic resection with CR confirmation (n=166)
- Current state : Completion of Enrollment